Compare TIC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIC | IMNM |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | TIC | IMNM |
|---|---|---|
| Price | $9.51 | $24.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $14.63 | ★ $31.22 |
| AVG Volume (30 Days) | ★ 2.3M | 2.0M |
| Earning Date | 03-27-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,284,070,000.00 | $9,679,000.00 |
| Revenue This Year | $41.97 | N/A |
| Revenue Next Year | $42.94 | $11.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $8.76 | $5.15 |
| 52 Week High | $14.94 | $27.65 |
| Indicator | TIC | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 28.12 | 57.35 |
| Support Level | $8.90 | $23.86 |
| Resistance Level | $10.21 | $27.65 |
| Average True Range (ATR) | 0.46 | 1.63 |
| MACD | -0.22 | -0.08 |
| Stochastic Oscillator | 3.10 | 62.94 |
TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.